News & Events

HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial

TUCSON, Ariz., Aug. 09, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing (NGS) in a clinical trial conducted by the Worldwide Innovative Networking Consortium (WIN) investigating a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC).

HTG Molecular Diagnostics Expands Its IVD Agreement With Illumina to Increase the Number of Test Kits

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has amended and restated its IVD Test Development and Component Supply Agreement with Illumina to, among other things, extend the agreement term and increase the number of in-vitro diagnostic (IVD) test kits that may be developed for use with Illumina sequencing technology.

HTG Molecular Launches NGS-based microRNA Assay; Additional RNA, DNA Assays to Follow

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has entered the next-generation sequencing space with the launch of its first assay, which targets and sequences 2,275 microRNAs using its proprietary nuclease protection probe technology.

HTG Transcriptomics

HTG EdgeSeq RUO Panels

Categories

Filter by Topics